Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kim Wai Yu

Showing results (1-10 of 6) with videos related to

Pageof 1
Sort By:
BMC Cancer|March 23, 2018
Effective osimertinib treatment in a patient with discordant T790 M mutation detection between liquid biopsy and tissue biopsyIsa Mambetsariev, Lalit Vora, Kim Wai Yu, et al.
Breast Cancer Research and Treatment|December 9, 2017
A single institution experience with palbociclib toxicity requiring dose modificationsJun Gong, May Cho, Kim Wai Yu, et al.
Cancer Chemotherapy and Pharmacology|October 24, 2019
Characterization of infections and hypogammaglobulinemia treated with the combination of pertuzumab and trastuzumabJoanne E Mortimer, Laura Kruper, Jae Jung, et al.
Breast Cancer Research and Treatment|November 12, 2014
Skin/nail infections with the addition of pertuzumab to trastuzumab-based chemotherapyJoanne Mortimer, Jae Jung, Yuan Yuan, et al.
Breast (Edinburgh, Scotland)|December 4, 2014
Pathologic complete response rates in triple-negative, HER2-positive, and hormone receptor-positive breast cancers after anthracycline-free neoadjuvant chemotherapy with carboplatin and paclitaxel with or without trastuzumabArvind M Shinde, Jing Zhai, Kim Wai Yu, et al.
Plos One|November 7, 2019
Mutation and immune profiling of metaplastic breast cancer: Correlation with survivalMichelle Afkhami, Daniel Schmolze, Susan E Yost, et al.
Pageof 1

Showing results (1-10 of 6) with videos related to

Sort By:
Pageof 1
BMC Cancer|March 23, 2018
Effective osimertinib treatment in a patient with discordant T790 M mutation detection between liquid biopsy and tissue biopsyIsa Mambetsariev, Lalit Vora, Kim Wai Yu, et al.
Breast Cancer Research and Treatment|December 9, 2017
A single institution experience with palbociclib toxicity requiring dose modificationsJun Gong, May Cho, Kim Wai Yu, et al.
Cancer Chemotherapy and Pharmacology|October 24, 2019
Characterization of infections and hypogammaglobulinemia treated with the combination of pertuzumab and trastuzumabJoanne E Mortimer, Laura Kruper, Jae Jung, et al.
Breast Cancer Research and Treatment|November 12, 2014
Skin/nail infections with the addition of pertuzumab to trastuzumab-based chemotherapyJoanne Mortimer, Jae Jung, Yuan Yuan, et al.
Breast (Edinburgh, Scotland)|December 4, 2014
Pathologic complete response rates in triple-negative, HER2-positive, and hormone receptor-positive breast cancers after anthracycline-free neoadjuvant chemotherapy with carboplatin and paclitaxel with or without trastuzumabArvind M Shinde, Jing Zhai, Kim Wai Yu, et al.
Plos One|November 7, 2019
Mutation and immune profiling of metaplastic breast cancer: Correlation with survivalMichelle Afkhami, Daniel Schmolze, Susan E Yost, et al.
Pageof 1